FDA signals new window for companies with recent complete response letters after commissioner’s exit

After FDA Commissioner Marty Makary left, the agency indicated it will reconsider drugs that received complete response letters in the past year.

The move offers sponsors a chance to resubmit their applications, potentially shortening the time to market for therapies that were previously declined.

FDA has not detailed specific criteria, but the guidance suggests a more collaborative approach with applicants seeking to address the agency’s concerns.

Industry observers see this as a sign that the agency may be easing its stance on certain submissions, though the ultimate outcome will depend on the quality of the revised data.